Jim Kastenmayer
Algemeen Adviseur bij ARRIVENT BIOPHARMA, INC.
Vermogen: 143 362 $ op 31-05-2024
Actieve functies van Jim Kastenmayer
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ARRIVENT BIOPHARMA, INC. | Algemeen Adviseur | 01-09-2023 | - |
Bedrijfssecretaris | 01-09-2023 | - |
Loopbaan van Jim Kastenmayer
Eerdere bekende functies van Jim Kastenmayer
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SPYRE THERAPEUTICS, INC. | Algemeen Directeur | 24-08-2022 | 29-11-2022 |
Algemeen Adviseur | 15-07-2021 | 16-05-2023 | |
President | 24-08-2022 | 29-11-2022 | |
Bedrijfssecretaris | 29-11-2022 | 16-05-2023 | |
VIELA BIO, INC. | Algemeen Adviseur | 01-01-2020 | 01-03-2021 |
Bedrijfssecretaris | 01-01-2020 | 01-03-2021 | |
ASTRAZENECA PLC | Algemeen Adviseur | 01-05-2012 | 01-12-2019 |
Medimmune, Inc. | Corporate Officer/Principal | - | - |
Opleiding van Jim Kastenmayer
Georgetown University Law Center | Graduate Degree |
Michigan State University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Verenigd Koninkrijk | 2 |
Operationeel
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 6 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
SPYRE THERAPEUTICS, INC. | Health Technology |
ARRIVENT BIOPHARMA, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
- Beurs
- Insiders
- Jim Kastenmayer
- Ervaring